|
Indian Pediatr 2010;47: 517-519 |
 |
Efficacy and Safety of Anti-D for Immune
Thrombocytopenic Purpura in Children |
Rahul Naithani, Rajat Kumar, M Mahapatra, Seema Tyagi and Pravas Mishra
From the Department of Hematology, All India Institute of
Medical Sciences, New Delhi, India.
Correspondence to: Dr Rahul Naithani, Pediatric
Hematology/Oncology and BMT Unit, The Hospital for Sick Children, Toronto,
Canada.
Email: [email protected]
Received: June 25, 2008;
Initial review: September 5, 2008;
Accepted: June 9, 2009.
Published online: 2009 September 03.
PII: S097475590800401-2
|
Abstract
This study was conducted in 20 children (16 males)
(mean age 9.2 ± 4.34y) with immune thrombocytopenic purpura (ITP) to
assess the response to anti-D immunoglobulin. Six patients had newly
diagnosed ITP, 6 had persistent ITP and 8 had chronic ITP. The overall
response rate was 70% (14/20). The median time to response was 3 days
(1-13 days). Response to anti-D was not related to age, sex, severity of
bleeding, platelet counts at presentation, ABO blood group, or prior
steroid or IVIG response.
Key words: Anti D, Children, Immune thrombocytopenic purpura.
|
The
decision to treat children with ITP is driven by fear of severe bleeding,
especially intracranial hemorrhage(1,2). Randomized clinical trials have
demons-trated that therapy with intravenous immune globulin (IVIg)
shortens the duration of severe thrombocytopenia faster than oral
prednisolone. However, the relative efficacy of these two regimens is
unresolved(1). Anti D is an antibody to the D (Rh) antigen(3). This
prospective study was planned, as there is no published clinical trial on
safety and efficacy of anti-D in ITP in Indian children.
Methods
This open label, non-comparative prospective trial was
conducted after IRB approval. Inclusion criteria were ITP patients with
bleeding symptoms; platelet counts<30,000/mm 3,
Rh-positive blood group and who were non-splenectomized. Bleeding symptoms
were graded as described elsewhere(4).
Patients were classified as: Newly-diagnosed ITP:
within 3 months from diagnosis; Persistent ITP: between 3 to 12 months
from diagnosis; and, Chronic ITP: lasting for more than 12 months, as per
current consensus definitions(5).
Anti D (WinRho,
Cangene, Winnipeg, MB) 50 µg/Kg was given intravenously single dose over
5-minute as infusion. Platelet counts were done on days 1, 2, 3 and 7 and
then at weekly interval after anti-D infusion. Response was defined as
Complete (CR): platelet count
ł100×109/L;
Response (R): platelet count
ł30×109/L
and at least twofold in-crease from the baseline count; and No response
(NR): platelet count <30×109/L or less than twofold increase of baseline
platelet count or bleeding(5). Time to response was calculated as time
taken from starting anti-D to achievement of CR or R. Loss of CR or R:
platelet count below 100×109/L or bleeding (from CR) or below 30×109/L or
less than twofold increase of baseline platelet count or bleeding (from
R).
Results
There were 16 males and 4 females. The mean age of the
study cohort was 9.2 ± 4.3 years. Six patients had newly diagnosed ITP, 6
patients had persistent ITP and 8 had chronic ITP. One patient had no
bleeding but was administered anti-D twice, first for maxillary biopsy,
which revealed mucormycosis and subsequent dose for eventration of her
left eye. There were 6 children with grade 1 bleeding, 11 children with
grade 2 bleeding and 2 patients with grade 4 bleeding.
The median platelet count at the time of administering
the anti-D was 8×10 9/L (2-22×109/L).
Median hemoglobin (Hb) was 12.9 g/dL (10.2-14 g/dL). Eight patients
had received prednisolone (1.5-7 months, median 5 months) prior to
administration of anti-D. In addition, 2 children had previously received
prednisolone but were 4 months and 10 months off steroid at the time of
administration of anti-D. One child had received IVIg 21 days prior to
administration of anti-D and had again presented with thrombocytopenia and
purpuric spots. One child was receiving dapsone since 6 months. Three
patients had not received any prior treatment. The overall response
rate was 70% (14/20) (Table I).
TABLE I
Response Rates in Immune Thrombocytopenic Purpura (ITP) (N=20)
ITP |
n |
Complete |
Response |
No |
Overall |
|
|
response |
|
response |
response |
Newly diagnosed |
6 |
2 |
3 |
1 |
5 (83%) |
Persistent |
6 |
2 |
3 |
1 |
5 (83%) |
Chronic |
8 |
1 |
3 |
4 |
4 (50%) |
Response kinetics: The median time to response was
3 days (1-13days). Only one patient responded in 24 hours of
administration of anti D. Three patients responded in 48 hours. There was
no correlation of response with age, sex, severity of bleeding, presenting
platelet counts, ABO blood group, or prior steroid or IVIG response. One
patient continued to have purpuric spots even after normalization of
platelet counts. He had an unclassified platelet function defect. One
child went into sustained remission (likely spontaneous remission). Rest
all patients had loss of response after a variable period of time. The
median duration of response was 21 days (14-53 days).
Some of the patients received repeat administration of
anti-D after loss of response. Four patients received 2 doses
and one child received 3 doses. Of these 5 patients; 1
PR went into CR on second dose, 1 PR again went into PR and
1 patient (PR) did not respond to second dose. One child, who
received 3 doses, attained CR with all the doses. One child who failed to
respond to first course, failed again with the second dose also.
Intravenous administration was associated with low
grade fever in 2 patients. We observed fall in hemoglobin (Hb) in 18 (90%)
patients. The average fall in Hb was 1.1 (0.4-2.0) g/dL. Polychromasia and
sherocytosis was seen in 13 and 2 patients, respectively. Median
reticulocyte count was 2.9% (1-7%). Median bilirubin rise was 0.9
(0.9-1.5) mg/dL. One patient had Hb fall of 2 g/dL but he had bleeding
manifestations also. The fall in Hb was transient and recovered in 7-14
days in all cases.
Discussion
Intravenous anti-D treatment compares favorably with
IVIg with a shorter infusion time (minutes), a single infusion,
much smaller donor pool size and therefore, less risk of infection
transmission and a lower cost compared with IVIg(6).
The presumed mechanism of action of anti-D
immunoglobulin in ITP involves extravascular hemolysis of
anti-D–sensitized red blood cells (RBCs) by splenic macrophages, which
results in decreased splenic sequestration of autoantibody-sensitized
platelets and an increased platelet count(3,6). Different trials have
reported overall response rates of 67-92%(6-15). One earlier Indian study
using intramuscular preparation documented a response of 62.5%(10).
The most frequent drug-related adverse events are
chills, pyrexia, fall in Hb, and increase in bilirubin. However, major
side effect reported includes prolonged intravascular hemolysis. Thus,
utmost care should be taken while using the drug in patients with
borderline hemoglobin.
There is evidence that a dose of 75 µg/Kg is more
effective than 50 µg/kg(7,8). Larger trials are required to find if this
dose would lead to higher response rates in Indian children with ITP.
Contributors: RN, RK and MM planned the study. ST
helped in diagnosis of cases. All the authors were involved in the
execution of the protocol. RN drafted the script, which was critically
analyzed by all the authors.
Funding: None.
Competing interests: Some children received free
Anti-D injections from Cangene Corporation.
What This Study Adds?
• Use of Anti-D immunoglobulin in ITP provided an overall 70%
response rate.
|
References
1. Cines DB, Blanchette VS. Immune thrombo-cytopenic
purpura. N Engl J Med 2002; 346: 995-1008.
2. Arnold DM, Kelton JG. Current options for the
treatment of idiopathic thrombocytopenic purpura. Semin Hematol 2007; 44 (suppl
5): s12-s23.
3. Rho(D) immune globulin intravenous (Human): WinRho®
SDF. Cangene Corporation, Winnipeg, MB, Canada R3T 5Y3 [professional
package insert], October 2004.
4. Mazzucconi MG, Fazi P, Bernasconi S, De Rossi G,
Leone G, Gugliotta L, et al. Therapy with high-dose dexamethasone
(HD-DXM) in previously untreated patients affected by idiopathic
thrombo-cytopenic purpura: a GIMEMA experience. Blood 2007; 109:
1401-1407.
5. Rodeghiero F, Stasi R, Gernsheimer T, Michel M,
Proven D, Arnold DM, et al. Standardization of terminology,
definitions and outcome criteria in immune thrombocytopenic purpura of
adults and children: report from an international working group. Blood
2009; 113: 2386-2393.
6. Scradavou A, Woo B, Woloski BMR, Cunningham-Rundles,
Ettinger LJ, Aledort LM, et al. Intravenous Anti D in treatment of
immune thrombocytopenic purpura: experience of 272 patients. Blood 1997;
89: 2689-2700.
7. Newman GC, Novoa MV, Fodero EM, Lesser ML, Woloski
BMR, Bussel JB. A dose of 75 µg/kg/d of i.v. anti-D increases the platelet
count more rapidly and for a longer period of time than 50 µg/kg/d in
adults with immune thrombocytopenic purpura. Br J Haematol 2001; 112:
1076-1078.
8. Tarantino MD, Young G, Bertolone SJ, Kalinyak KA,
Shafer FE, Kulkarni R, et al. Single dose of anti-D immune globulin
at 75 microg/kg is as effective as intravenous immune globulin at rapidly
raising the platelet count in newly diagnosed immune thrombocytopenic
purpura in children. J Pediatr 2006; 148: 489-494.
9. El Alfy MS, Mokhtar GM, El-Laboudy MA, Khalifa AS.
Randomized trial of anti-D immunoglobulin versus low-dose intravenous
immunoglobulin in the treatment of childhood chronic idiopathic
thrombocytopenic purpura. Acta Haematol 2006; 115: 46-52.
10. Krishnamurti L, Charan VD, Desai N, Pati H,
Choudhry VP. Anti-D immunoglobulin in the treatment of idiopathic
thrombocytopenic purpura. Indian J Pediatr 1994; 61: 179-182.
11. Blanchette V, Imbach P, Andrew M, Adams M, McMillan
J, Wang E, et al. Randomised trial of intravenous immunoglobulin G,
intravenous anti-D, and oral prednisone in childhood acute immune
thrombocytopenic purpura. Lancet 1994; 344: 703-707.
12. Kumar M, Vik TA, Johnson CS, Southwood ME, Croop JM.
Treatment, outcome, and cost of care in children with idiopathic
thrombocytopenic purpura. Am J Hematol 2005; 78: 181-187.
13. Kjaersgaard M, Hasle H. A review of Anti D
treatment of childhood idiopathic thrombocyto-penic purpura. Pediatr Blood
Cancer 2006; 47: 717-720.
14. Freiberg A, Mauger D. Efficacy, safety, and dose
response of intravenous anti-D immune globulin (WinRho SDF) for the
treatment of idiopathic thrombocytopenic purpura in children. Semin
Hematol 1998; 35: 23-27.
15. Moser AM, Shalev H, Kapelushnik J. Anti-D exerts a
very early response in childhood acute idiopathic thrombocytopenic purpura.
Pediatr Hematol Oncol 2002; 19: 407-411.
|
|
 |
|